HeXun Biosciences Co., Ltd. (TPEX:6986)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
58.00
-0.20 (-0.34%)
Feb 11, 2026, 1:17 PM CST
Market Cap2.68B -17.4%
Revenue (ttm)290.83M +14.0%
Net Income112.31M -15.8%
EPS2.44 -15.8%
Shares Out46.00M
PE Ratio23.85
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume49,234
Average Volume75,734
Open57.80
Previous Close58.20
Day's Range57.50 - 59.80
52-Week Range51.80 - 91.30
Beta-0.16
RSI40.06
Earnings DateMar 31, 2026

About HeXun Biosciences

HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 45
Stock Exchange Taipei Exchange
Ticker Symbol 6986
Full Company Profile

Financial Performance

In 2024, HeXun Biosciences's revenue was 286.42 million, an increase of 119.36% compared to the previous year's 130.57 million. Earnings were 147.22 million, an increase of 339.62%.

Financial Statements